JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Improving Patient Compliance with Biopharmaceuticals by Reducing Injection-Associated Pain
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Improving Patient Compliance with Biopharmaceuticals by Reducing Injection-Associated Pain
So, Jineon;
  PDF(new window)
 Abstract
Biopharmaceuticals, with their ability to treat many unmet needs, are seen as promising medications in diabetes mellitus, growth hormone deficiency, chronic renal failure, cancer, and rheumatoid arthritis. However, almost all biopharmaceuticals should be administrated by injection; IV, IM, and SC. In addition, these treatments are long term, and patients should receive frequent injections for many years. Patient compliance is therefore of critical importance to ensure treatment benefits. Therefore, the goal of drug product development should be focused on improving patient compliance by reducing injection-associated pain as well as stable formulation development. This review will suggest the kinds of factors that should be considered to minimize injection pain with regard to formulation, device, and injection procedures focused on SC injections.
 Keywords
Injection pain;Compliance;Formulation;Needle;Excipient;
 Language
English
 Cited by
 References
1.
Geary DF, Keating LE, Vigneux A, Stephens D, Hebert D, Harvey EA. Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 2005;68:1759-65. crossref(new window)

2.
Cummings EA, Reid GJ, Finley GA, McGrath PJ, Ritchie JA. Prevalence and source of pain in pediatric inpatients. Pain 1996;68:25-31. crossref(new window)

3.
Dahlquist LM, Gil KM, Armstrong FD, DeLawyer DD, Greene P, Wuori D. Preparing children for medical examinations: the importance of previous medical experience. Health Psychol 1986;5:249-59. crossref(new window)

4.
Frenken LA, van Lier HJ, Jordans JG, Leunissen KM, van Leusen R, Verstappen VM, Koene RA. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 1993;22:553-6. crossref(new window)

5.
Laursen T, Hansen B, Fisker S. Pain Perception after Subcutaneous Injections of Media Containing Different Buffers. Basic Clin Pharmacol Toxicol 2006;98:218-21. crossref(new window)

6.
Kappelgaard AM1, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid Growth Hormone: Preservatives and Buffers. Horm Res 2004;62(suppl 3):98-103. crossref(new window)

7.
Fransson J1, Espander-Jansson A. Local Tolerance of Subcutaneous Injections. J Pharm Pharmacol 1996;48:1012-5. crossref(new window)

8.
Gill HS1, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol 2007;1:725-9. crossref(new window)